---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021513"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:25:24.375378+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# iMDx reports Q3 2025 net loss of $10.9M, advances toward FDA submission for GraftAssureDx by year-end

## Summary
- Revenue $260k from lab services; gross margin 53.5%; net loss $10.9M ($0.34/sh); cash $20.2M.
- On track to submit GraftAssureDx for FDA review by year-end; expect mid-2026 commercial launch.
- 19 transplant centers engaged with GraftAssure technology; goal of 20 by year-end; 11 clinical trial sites.
- Operating expenses $11.2M include $3.4M non-cash contingent consideration change; R&D up 18% QoQ to $3.9M.
- New VP Marketing Steven Tahmooressi hired; registry study of 5,000 patients planned; expanding into heart transplant testing.

## SEC filing metadata
- accession: 0001493152-25-021513
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/0001493152-25-021513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315225021513/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021513
- JSON: https://secwatch.observer/filing/0001493152-25-021513.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021513.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.